Investigative journalists Jeanne Lenzer and Shannon Brownlee uncovered a trove of information about the recently approved Alzheimer’s drug donanemab, (brand name Kisunla). Their deeply reported article in the September 25 issue of The BMJ highlighted questionable clinical trial results to potentially unethical behavior — including payments and industry ties — among some FDA advisory committee…